Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial

IMPORTANCE: Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. OBJECTIVE: To evaluate clinical outcomes when HAI chemoth...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Cercek, Andrea, Boerner, Thomas, Tan, Benjamin R., Chou, Joanne F., Gönen, Mithat, Boucher, Taryn M., Hauser, Haley F., Do, Richard K. G., Lowery, Maeve A., Harding, James J., Varghese, Anna M., Reidy-Lagunes, Diane, Saltz, Leonard, Schultz, Nikolaus, Kingham, T. Peter, D’Angelica, Michael I., DeMatteo, Ronald P., Drebin, Jeffrey A., Allen, Peter J., Balachandran, Vinod P., Lim, Kian-Huat, Sanchez-Vega, Francisco, Vachharajani, Neeta, Majella Doyle, Maria B., Fields, Ryan C., Hawkins, William G., Strasberg, Steven M., Chapman, William C., Diaz, Luis A., Kemeny, Nancy E., Jarnagin, William R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2019
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824231/
https://ncbi.nlm.nih.gov/pubmed/31670750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.3718
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi